COMMUNIQUÉS West-GlobeNewswire

IHA’s Symphony Chosen As Provider Directory Data Source for Covered California
14/03/2024
Symphony simplifies complex data exchange processes to ensure more accurate provider directory data for the state health insurance marketplace OAKLAND, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- The Integrated [...]
Sino Biological Announces Services Partnership with Rapid Novor
14/03/2024
Sino Biological and Rapid Novor partner to offer combined antibody development and sequencing services BEIJING, China, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire — Sino Biological, Inc. (“Sino Biological” or [...]
SafeGuard Surgical Receives FDA "Breakthrough" Designation, Secures Funding from Tom Pepin and NFL QB Jameis Winston
14/03/2024
Tampa, FL, March 14, 2024 (GLOBE NEWSWIRE) -- SafeGuard Surgical , a leading medical technology company focused on life-saving biodegradable solutions, announced today a major milestone in its mission to improve global [...]
Rick Simpson Oil California Introduces RSO Suppositories A New Path to Wellness Through Direct Absorption
14/03/2024
Rick Simpson Oil California Offers New RSO Suppositories for a Natural, Effective Alternative for Diverse Health Conditions LOS ANGELES, March 14, 2024 (GLOBE NEWSWIRE) -- In expanding its natural health remedies, Rick [...]
Revolutionizing Chronic Kidney Disease Management on World Kidney Day
14/03/2024
LifeLabs Klinrisk Score Included in KDIGO 2024 CKD Guideline Toronto, March 14, 2024 (GLOBE NEWSWIRE) -- Today, as the world marks World Kidney Day, LifeLabs, in exclusive partnership with Klinrisk, proudly announces a [...]
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
14/03/2024
FREMONT, CA, March 14, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ: ABVC) (“Company”), a biotechnology company specializing in botanically based solutions that deliver high efficacy and low [...]
Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit
14/03/2024
Presentation Will Discuss Cellular Immunotherapy’s Potential Role in Treating Chronic Conditions and Extending People’s Lives FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ: CELU) (“ [...]
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
14/03/2024
NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel [...]
Astra Plastic Surgery adds double board-certified facial plastic surgeon to acclaimed roster
14/03/2024
Acclaimed plastic facial surgeon now practicing at Alpharetta and Cumming locations ATLANTA, March 14, 2024 (GLOBE NEWSWIRE) -- Astra Plastic Surgery, an acclaimed North Georgia-based cosmetic and reconstructive surgery [...]
NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy
14/03/2024
WOBURN, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted the recent publication of a large study demonstrating that DPNCheck ® combined with standard EKG or DPNCheck alone accurately [...]
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
14/03/2024
GRANTS, NEW MEXICO, March 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) Today announced that BGXX will install a 102-megawatt solar field to power the electricity [...]
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
14/03/2024
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for Efficacy Complete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating Serious Condition of [...]
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
14/03/2024
According to the World Health Organization, 3 of 5 people worldwide die due to chronic inflammatory diseases, which are considered the most significant cause of death in the world. ZyVersa is developing Inflammasome ASC [...]
VitalHub Announces Q4 2023 Conference Call Date
14/03/2024
TORONTO, March 14, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) (TSX: VHI) (OTCQX:VHIBF) is pleased to announce that it will release its financial results for its quarter ended December 31 st , [...]
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
14/03/2024
- Presented initial data from Phase 1 ELiPSE-1 Trial of CNTY-101 in relapsed/refractory B-cell lymphomas demonstrating a favorable tolerability profile, early clinical activity and indication that Allo-Evasion™ may [...]
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
14/03/2024
Guidelines highlight the importance of risk prediction and personalized treatment to reduce risk LONDON and SALT LAKE CITY, March 14, 2024 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) (Renalytix) [...]
Monte Rosa Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
14/03/2024
MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing in ongoing Phase 1/2 clinical trial; program on track with determination of recommended Phase 2 dose expected in Q2 2024 [...]
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
14/03/2024
Cullinan remains on track to report additional solid tumor dose escalation data for CLN-619 in the second quarter of 2024 and recently received FDA clearance for an IND to evaluate CLN-619 in relapsed/refractory [...]
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update
14/03/2024
AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update ACI-24.060 ABATE Phase 2 trial to report Abeta-PET imaging results in Q2 and H2 ACI-7104.056 VacSYn Phase 2 trial in Parkinson’s disease [...]

Pages